These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 29537892)

  • 1. Efficacy of dapagliflozin as an adjunct therapy in patients with inadequately controlled type 1 diabetes mellitus.
    Van den Mooter L; Caerels S; Mathieu C
    Expert Opin Pharmacother; 2018 Apr; 19(6):617-622. PubMed ID: 29537892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dapagliflozin for the treatment of type 1 diabetes mellitus.
    Pafili K; Maltezos E; Papanas N
    Expert Opin Investig Drugs; 2017 Jul; 26(7):873-881. PubMed ID: 28587531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial.
    Mathieu C; Dandona P; Gillard P; Senior P; Hasslacher C; Araki E; Lind M; Bain SC; Jabbour S; Arya N; Hansen L; Thorén F; Langkilde AM;
    Diabetes Care; 2018 Sep; 41(9):1938-1946. PubMed ID: 30026335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dapagliflozin: A Review in Type 1 Diabetes.
    Paik J; Blair HA
    Drugs; 2019 Nov; 79(17):1877-1884. PubMed ID: 31664708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.
    Carlson CJ; Santamarina ML
    Expert Opin Drug Saf; 2016 Oct; 15(10):1401-12. PubMed ID: 27449721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes.
    Herring RA; Shojaee-Moradie F; Garesse R; Stevenage M; Jackson N; Fielding BA; Mendis A; Johnsen S; Umpleby AM; Davies M; Russell-Jones DL
    Diabetes Care; 2020 Sep; 43(9):2128-2136. PubMed ID: 32641376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.
    Shah NK; Deeb WE; Choksi R; Epstein BJ
    Pharmacotherapy; 2012 Jan; 32(1):80-94. PubMed ID: 22392830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes.
    Lamos EM; Younk LM; Davis SN
    Expert Opin Investig Drugs; 2014 Jun; 23(6):875-82. PubMed ID: 24746173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
    Vivian EM
    Am J Health Syst Pharm; 2015 Mar; 72(5):361-72. PubMed ID: 25694411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium/glucose cotransporter 2 inhibitors for the treatment of type 1 diabetes: what are the latest developments?
    Veneti S; Tziomalos K
    Expert Opin Pharmacother; 2021 Nov; 22(16):2261-2266. PubMed ID: 34402702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT inhibitor adjunct therapy in type 1 diabetes.
    McCrimmon RJ; Henry RR
    Diabetologia; 2018 Oct; 61(10):2126-2133. PubMed ID: 30132030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dapagliflozin: more than just another oral glucose-lowering agent?
    Katsiki N; Papanas N; Mikhailidis DP
    Expert Opin Investig Drugs; 2010 Dec; 19(12):1581-9. PubMed ID: 21105857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.
    Scheen AJ
    Expert Opin Drug Saf; 2015; 14(12):1879-904. PubMed ID: 26513131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT-2 Inhibitors in Type 1 Diabetes Mellitus: A Comprehensive Review of the Literature.
    Patoulias D; Imprialos K; Stavropoulos K; Athyros V; Doumas M
    Curr Clin Pharmacol; 2018; 13(4):261-272. PubMed ID: 30084335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dapagliflozin: A Sodium Glucose Cotransporter 2 Inhibitor for the Treatment of Diabetes Mellitus.
    Davis PN; Ndefo UA; Oliver A
    J Pharm Pract; 2016 Apr; 29(2):165-71. PubMed ID: 25609661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dapagliflozin combination therapy in type 2 diabetes mellitus.
    Yacoub T
    Postgrad Med; 2016 Jan; 128(1):124-36. PubMed ID: 26571022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin.
    Nauck MA; Del Prato S; Durán-García S; Rohwedder K; Langkilde AM; Sugg J; Parikh SJ
    Diabetes Obes Metab; 2014 Nov; 16(11):1111-20. PubMed ID: 24919526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
    Davidson JA; Kuritzky L
    Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Network Meta-Analysis of the Dose-Response Effects of Dapagliflozin on Efficacy and Safety in Adults With Type 1 Diabetes.
    Li Y; Li H; Dong L; Lin D; Xu L; Lou P; Zang D; Wang K; Ma L
    Front Endocrinol (Lausanne); 2022; 13():923376. PubMed ID: 35872994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.